Ispire Technology Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended June 30, 2023, compared with fiscal 2022. The request metadata says “2022 Q4,” but the supplied filing is an annual report for FY2023, not a standalone 2022 fourth-quarter filing.
Business context
Ispire develops, markets and sells tobacco vaping hardware under Aspire and cannabis vaping hardware under Ispire. Tobacco products are sold internationally, primarily through distributors; cannabis hardware sales are primarily ODM sales to other brands in the United States. The company reported one operating segment. Its products are manufactured by Shenzhen Yi Jia, a related party 95% owned by co-CEO and controlling stockholder Tuanfang Liu.
Financial results and liquidity
| Metric | FY2022 | FY2023 |
|---|---|---|
| Revenue | $88.1 million | $115.6 million |
| Gross profit / margin | $13.3 million / 15.1% | $21.1 million / 18.2% |
| Operating expenses | $14.3 million | $25.6 million |
| Operating loss | $1.0 million | $4.6 million |
| Net loss | $1.9 million | $6.1 million |
| Operating cash flow | $(7.6) million | $(7.6) million |
- FY2023 revenue increased 31.2%. Cannabis revenue approximately doubled to $40.0 million; tobacco revenue rose to $75.6 million. Cannabis gross margin increased to 22.9% from 13.5%, while tobacco margin was broadly stable at 15.7%.
- General and administrative expense rose to $20.9 million, primarily reflecting expansion-related payroll, bad-debt charges, patent costs, facility costs and professional fees. The company recorded $3.3 million of accounts-receivable impairment; year-end net receivables were $24.5 million.
- At June 30, 2023, cash and cash equivalents were $40.3 million, with a $9.1 million held-to-maturity certificate of deposit; current assets were $84.8 million and current liabilities $56.0 million, for working capital of $28.8 million. Cash was $74.5 million a year earlier.
- FY2023 investing cash outflow was $10.2 million, including $9.1 million for the certificate of deposit and $1.0 million for property and equipment. Financing cash outflow was $16.4 million, despite IPO and private-placement proceeds, largely because of repayments to related parties and dividend payments.
- No conventional interest-bearing borrowings are shown in the supplied balance sheet. However, current liabilities included $51.7 million of accounts payable to a related party, and the filing also reports $4.3 million of operating lease liabilities. Related-party balances are described as unsecured, non-interest-bearing and, in some cases, repayable on demand.
Changes, outlook and material risks
- Capital and liquidity: The April 2023 IPO generated approximately $18.3 million net proceeds, and a June private placement generated approximately $7.4 million net. Management said available cash, operating cash flows and IPO proceeds were expected to meet working-capital needs for the next 12 months, while cautioning that additional financing may be needed under adverse conditions or if growth is accelerated.
- Manufacturing plans: The company planned to begin assembly operations at its California facility and was exploring Southeast Asia. The filing gives inconsistent timing: it refers to expected initial California production before the end of 2023 in one passage and before the first half of 2024 in another. These are plans, not assured outcomes.
- Accounting and controls: Interim 2023 financial statements were restated after intellectual property transferred by a controlling stockholder was initially recorded at a $74.3 million fair value rather than the transferor’s nil carrying value. The company reported ineffective disclosure controls and a material weakness in internal control over financial reporting; it said it was implementing remediation and had appointed a new CFO and vice president of finance after year-end. The independent auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- Regulatory exposure: A PMTA for the Nautilus Prime tobacco product line remains pending with the FDA; the company says it stopped marketing tobacco vaping products in the United States because the permitted product line did not justify regulatory and marketing costs. The FDA has not substantively responded to its 2021 request for social-media marketing records, and further action cannot be ruled out. Cannabis sales are concentrated in the United States and depend on changing state and federal rules, shipping restrictions and enforcement interpretations.
- Concentration and related-party governance: One distributor generated about 32% of FY2023 revenue. Shenzhen Yi Jia accounted for 92% of FY2023 purchases and is controlled by the co-CEO, who also has substantial voting control of Ispire. The filing describes related-party supply terms and audit committee oversight, but the supplier dependence and conflicts remain material risks.
- Other risks and contingencies: The filing cites product-liability and health concerns, limited insurance (Aspire Science has no product-liability insurance), supply-chain disruption, customer credit risk, competition, and uncertainty around cannabis legalization. No material litigation is identified apart from the unresolved FDA inquiry described above. No specific revenue, earnings or margin guidance is provided.
- Ownership: The co-CEO and his wife beneficially owned 65.2% of common stock as of September 15, 2023. The company reported 54,856,231 shares outstanding on that date.
Investor verification priorities
- Check subsequent SEC disclosures on remediation of the material weakness, financial reporting controls and any further restatements.
- Verify the California manufacturing start date, actual production, spending and progress toward reducing dependence on Shenzhen Yi Jia.
- Review the related-party supply agreements, pricing approvals, outstanding balances and any subsequent changes in the supplier relationship.
- Reconcile the related-party accounts-payable disclosures: the balance sheet reports $51.7 million at June 30, 2023, while a related-party note reports $55.8 million.
- Track collection of receivables, the status of disputed customer accounts and allowance levels, given the $3.3 million impairment and elevated year-end receivables.
- Monitor the FDA’s pending PMTA and social-media inquiry, and any changes to U.S. vaping, cannabis or delivery regulations that could affect the business.